HealthEconomics.Com - The Resource for Health Outcomes Professionals

search   
Sign Up For Our Newsletter
Email:  


industry news

Direct-to-consumer communication by pharmaceutical companies ? Europeans deserve better

FDA Final Guidance on Patient-Reported Outcome (PRO) Measures: Use in Medical Product Development to Support Labeling Claims

Employers plan to shift more health-care costs to workers, survey reports By David S. Hilzenrath

Characteristics of Published Comparative Effectiveness Studies of Medication by Michael Hochman, MD; Danny McCormick, MD, MPH

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

Health Care Reform — Where Do We Go from Here?

"Interpreting Hazards: The Increasing Importance of "Antidote to Anecdote" in Managed Care" by Fairman et al

"Is "Value-Based" Value Wasted? Examining Value-Based Insurance Designs Through the Lens of Cost-Effectiveness" by Melnick et al

58% of Surgeries Performed in Hospitals are Outpatient, According to AHRQ/HCUP survey.

AHRQ Introduces New Online Technical Tutorial Series With First Module on HCUP Sample Design

Doctors Face 21% Cut In Medicare Payments.

AMCP Issues Summary of White House Health Care Reform Summit

Maximus To Continue Reviewing Medicare Part D Plan Coverage Determinations

Pharmacoeconomics to Get Bigger Budgets, According to Preliminary Survey Results (Source=Marketwire)

Healthcare Rationing by Proxy: Cost-Effectiveness Analysis and the Misuse of the $50,000 Threshold in the US by Bridges et al.

The AMCP Format for Formulary Submissions, Version 3.0

Statistical Data Resources from AMCP for benchmarking in managed care

UnitedHealthcare has launched an innovative program that offers $20 discounts off certain prescription drug co-payments

Healthcare Technology News: National Health Expenditures Top 17% of GDP

UnitedHealthcare Creates Adult National Cancer Care Registry with Data and Analysis to Support Oncologists in the Fight against Cancer

Novartis’s Afinitor Cancer Drug Rejected by U.K. Cost Agency

NEJM: “Giving Teeth to Comparative-Effectiveness Research — The Oregon Experience” by Saha et al.

Oncology Innovative Pricing deal with NICE on lung cancer drug

“Medication Adherence and Enrollment in a Consumer-Driven Health Plan” by Chen,

FDA News: NICE Outlines Appeals Process for Drug Determinations

IBI: More Than Health Promotion: How Employers Manage Health and Productivity

PR Hub: NICE Recommends Approval of New Rheumatoid Arthritis (RA) Treatment Cimzia(R) (certolizumab pegol) With First of its Kind RA Patient Access Scheme

Healthcare Technology News: Privacy Survey - In Providers We Trust

NEJM article: ‘ Uncomfortable Arithmetic — Whom to Cover versus What to Cover’ by K. Baicker and A. Chandra

NEJM article: ‘ “Play-or-Pay” Insurance Reforms for Employers — Confusion and Inequity’ by B. Herring and M.V. Pauly

Centre for Reviews and Dissemination: Cost-effectiveness of interventions to promote physical activity: a modelling study

Do Health Politicians Really Listen to Health Economists? Observations from Europe by Mittendorf et al.

The Hospitalist: Evidence-Based Medicine Curveball

Health Care Reform and the Need for Comparative-Effectiveness Research

January 2010 Newsletter and Eisenberg Conference Series 2009 Are Now Available

Disease Management Care Blog: 10 Predictions for the Next Decade

Conference: Patient Experience and Patient Safety Culture, April 19-21

Funny Pharmacy Videos. These are Hysterical! Particularly "The PharmG's - Boom Intervention" Rap

hot jobs

Job Title Company
Director Healthcare Economics Medtronic
Senior Statistician Trinity Partners
Director, Center for Health Outcomes Research Univ of IL College of Medicine Peoria
Medical Writer PRMA Consulting Ltd
DIRECTOR, GHEOR, NEUROSCIENCE/IMMUNOSCIENCE/VIRGOLOGY Bristol-Myers Squibb


pharmacy resources

$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers
Personalize medicine, which targets individualized treatment and care based on personal and genetic variation, is creating a booming market, but it is a disruptive innovation that PricewaterhouseCoopers says will create both opportunities and challenges for traditional healthcare and emerging market participants. (Source: PR Newswire, New York, Dec. 8, 2009)
`Me-Too' Innovation in Pharmaceutical Markets
Critics of me-too innovation often argue that follow-on drugs offer little incremental clinical value over existing pioneer products, while at the same time increasing health care costs. We examine whether consumers view follow-on and pioneer drugs as close substitutes or distinct clinical therapies. (Source: Berkley Electronic Press, Vol. 12, Issue 1, 2009)
AMCP eDossier System
The AMCP eDossier System is a centralized, secure, web-based platform, that provides qualified health care decision makers the opportunity to easily access, review, and evaluate research to make informed, evidence-based decisions.
AMCP Releases Summary Of Proposed Medicare Part D Rule
In the Oct. 22nd Federal Register, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule calling for a significant number of policy and technical changes to Medicare Advantage and stand-alone Part D prescription drug plans.
Article: TO WHAT EXTENT DO CHANGES IN THIRD-PARTY PAYMENT AFFECT CLINICAL TRIALS AND THE EVIDENCE BASE?
Source: Duke Evidence-Based Practice Center Center for Clinical Health Policy Research, August 200
Asia Pacific Biotechnology Market (2008-2012): An Exhaustive View of the Biotechnology Markets in the Asia-Pacific Region
The report "Asia Pacific Biotechnology Market (2008-2012)" provides an exhaustive view of the biotechnology markets in the Asia-Pacific region. (Source: Gale, Cengage Learning, Business Wire, 2008)
Ask Your Virtual Pharmacist
A liscensed pharmacist will answer drug questions involving herbals, drug interactions, or other therapies for free.
Assurance Pharmaceutical Care Documentation Software
Assurance Pharmaceutical Care™ is a computer-based documentation system designed to support the practice of pharmaceutical care. This program is used by pharmaceutical care practitioners to manage all of a patient's medications and to document outcomes from drug therapies, cost savings, and clinical improvement in patient care. It supports all reimbursement methods and practitioners providing medication therapy management (MTM) services to patients on a continuous basis, over repeated patient encounters, at multiple practice sites, by multiple practitioners, and it is fully developed to support an entire network of practitioners.
Balancing Innovation, Access, and Profits — Market Exclusivity for Biologics
Balancing Innovation, Access, and Profits — Market Exclusivity for Biologics. (Source: Alfred B. Engelberg, J.D., Aaron S. Kesselheim, M.D., J.D., M.P.H., and Jerry Avorn, M.D., NEJM, October 2009)
Comparing Adherence and Persistence
The National Quality Forum recently endorsed the proportion of days covered (PDC)—a measure of medication adherence—as an indicator of quality in drug therapy management. (Source: J Manag Care Pharm. 2009;15(9):728-40 Copyright © 2009, Academy of Managed Care Pharmacy.)
Consumer Reports Opinion Poll: 66 of Americans Blindsides by Cost of Drugs
Consumer Reports opinion poll found that only 4% of respondents had discussed drug price with their physician at point of prescribing; 66% "blindsided" by costs once they reached the pharmacy.
Current and Future Directions in MS Management:
Based on surveys conducted..., several topics were identified for which pharmacists indicated a need for new and updated information. (Source: J Manag Care Pharm. 2009;15(9-a)(Suppl):S2-S15) Copyright © 2009, Academy of Managed Care Pharmacy
CVS Caremark Research Illustrates How Innovative Pharmacy Benefit Plan Design Optimizes Generic Utilization
The study found that implementing a $0 copay structure for generic medications can be an effective strategy to increase generic dispensing, with the generic dispensing rate (GDR) increasing to 60.8 percent (a 4.2 percent increase) during the study period. (Source: CVS Caremark Research, Reuters, October 2009)
Drug company targets critical doctors
Drug giant Merck compiled a “hit list” of doctors to “discredit” in order to stop criticism of their drugs, according to evidence released from the Vioxx drug trial in the US. (Source: Harriet Grecian, The Journal, Issue 26, Oct. 2009)
Drug company targets critical doctors
Drug giant Merck compiled a “hit list” of doctors to “discredit” in order to stop criticism of their drugs, according to evidence released from the Vioxx drug trial in the US. (Source: Harriet Grecian, The Journal, Issue 26, Oct. 2009)
DrugPipelineForecast
DrugPipelineForecast™ is a tool developed specifically for managed care professionals to address their unique needs. This is a site which can help you track late-phase pipeline:*Products in late phase III to approval stages * All types of information for an in-depth review * Tabulated format for a quick analysis * Search and filtering capabilities * Default and customized reports * Frequent updates
Emerging Trends Driving Changes in Pharmacy Benefits
Download report from website. The results of the fourth annual “Emerging Trends Driving Changes in Pharmacy Benefits” survey sponsored by the Foundation for Managed Care Pharmacy (FMCP) have been released. The survey is made possible through the generous support of Merck & Company. The HSM Group conducted the survey and analysis. Concerns about the management of specialty pharmacy continued to eclipse other issues in this year’s survey, both in terms of judging clinical evidence and cost management.
ePrescribe Florida
ePrescribe Florida is a collaborative framework of industry stakeholders working together to help accelerate physician adoption of electronic prescribing by fostering cooperation and coordination among prescribing constituents.
excellRX
Market leader in pharmaceutical care for niche disease markets, providing expert medication consultation and pharmaceutical distribution services. Combining proprietary technology and clinical experience, excelleRx ensures the appropriate use of medication, and thereby enhances quality of life. Also has a Medication Management Artificial Intelligence database: Our proprietary medication management system includes clinical decision support tools and a team of highly specialized doctorate level pharmacists.
Express Scripts
More than 50 million members, rich and diverse database on drug usage and demographics, and a history of partnering with pharmaceutical companies.
Global Biotech Market Analysis and Forecasts, 2008-2023
Paid Report (but a sample is downloadable for free): Global Biotech Market Analysis and Forecasts, 2008-2023, from Visiongain.com. This report covers both the top ten therapy classes as well as the top ten leading pharmaceutical products in the biotech market in particular, as well as leading pipeline agents. Includes forecasting, SWOT analysis, R&D assessments, qualitative evaluations.
How to Connect Patients and Physicians Around Your Brand
In this episode, Dr. Ball and Mr. LeVine discuss the importance of patient feedback — how to obtain it and how it can be used to better connect brands with patients and physicians in a practice setting.
Innovative Pricing Agreements, Risk Sharing, Market Access Agreements
This PDF summarizes a 2009 Brussels Conference on these types of pricing schemes (eg, Price/Volume, Expenditure Caps, Price Cuts, Conditional Discounts), with emphasis on Europe. Contains nice table with examples of schemes by drug/country. (Source: IMS Pharma Pricing & Reimbursement, August 2009)
Life After Average Wholesale Price (AWP): Preparing for the Next Generation of Drug Pricing
Webinar. You can buy the recording. Recent legal action against FirstDataBank is driving industry change regarding Average Wholesale Price (AWP). Find out how new pharmacy pricing benchmarks will impact price inflation for your plan and how to respond. Plus, hear about how to achieve optimal balance of price, member cost share and utilization management for improving value and cost performance of your pharmacy benefit.
MCP Format Version 3 and related documents
he AMCP Format for Formulary Submissions is a set of guidelines, a template that drug companies can use to prepare submissions of new and existing pharmaceuticals for a health system's Pharmacy and Therapeutics (P&T) Committee. Previously, P&T Committees often received drug information passively from pharmaceutical manufacturers that was biased and of poor quality. In this era of dramatically increasing drug costs, biotechnology, and information availability, the Format empowers health systems to pro-actively request specific information from manufacturers that will allow them to more accurately determine the total value that a drug brings to their population as the basis for accepting or rejecting a drug for its formulary.
MedicalMnemonics.com
You all probably remember On Old Olympus' Towering Top...well, this database has one for EVERYTHING!!! A free online searchable database of medical mnemonics to help students of health-related professions remember the important details.
MEPS data: Statistical Brief #245
MEPS data: Average number of total and refill prescriptions by select person characteristics (2006), Statistical Brief #245.
MEPS: Choice of ACEI and ACEII inhibitors for HTN
Medical Expenditure Panel Survey: Choice of ACEI and ACEII inhibitors for HTN
MEPS: Medical/Rx costs for asthma
Medical Expenditure Panel Survey: Medical/Rx costs for asthma and whether daily asthma prevention is being taken.
New Drug Pocketbinder for Pharmacy
Newly released drugs are listed and reviewed. The New Drug Pocketbinder provides brief, concise summaries of the latest new drug releases in pocketsized monograph format.
NEW REPORT: Latin American Pharmaceutical Market Outlook To 2014: Policy environment, market analysis, forecasts and growth opportunities
For more information on the cost/ content of this report contact Daniel Healy on 0044 207 551 9563 or dhealy@globalbusinessinsights.com
Oncology Index for Managed Care
The Zitter Group’s new Managed Care Oncology Index focuses on both payers and oncology practices, making it the most comprehensive and up-to-date analysis of the major trends underway in the evolving payer market for oncology. This unique study offers pharmaceutical marketers insight into trends in physician reimbursement, product selection, practice profitability, patient access, and how managed care organizations plan to pursue oncology cost-cutting.
P&T Community
An online resource for P&T committee members in hospital-based and managed care organizations. Formkit provides P&T members with pharmacoeconomic information, FDA and industry news, and access to the most up-to-date formulary kits.
P&T Perspective from The Zitter Group
The Zitter Group’s new simulated P&T meeting, P&T Perspective, offers pharmaceutical marketers objective and realistic insight into how their product will fare in a health plan P&T review. Unlike traditional Pharma sponsored mock P&T meetings, the composition and management of P&T Perspective closely mirrors the way that committees operate in the real world. The program uses Web-streaming technology to enable sponsors to watch the meeting anonymously, eliminating the bias inherent in a sponsored advisory board.
Pharma Marketing Blog
Blog from John Mack, publisher ofPharma Marketing News, a monthly e-newsletter
Pharma Marketing Blog: Unintentional Consequences of FDA Warnings
Do FDA Warning letters affect disease diagnosis? Look at the Lilly-funded antidepressant case study based on the PHARMetrics Patient-centric Database (now owned by IMS), described here in the Pharma Marketing Blog.
Pharma Marketing Blog: Unintentional Consequences of FDA Warnings
Do FDA Warning letters affect disease diagnosis? Look at the Lilly-funded antidepressant case study based on the PHARMetrics Patient-centric Database (now owned by IMS), described here in the Pharma Marketing Blog.
PharmaCE - Pharmacist & Technician Continuing Education
PharmaCE enables you to select continuing education articles published within the last three years from either The Annals of Pharmacotherapy or the journal of Pharmacy Technology.
Pharmaceutical databases online
Drug information resource. Over 75,000 approved drugs and health products. Include generic drugs, prescription drugs, nutritions, supplements, veterinary products, pet meds, cosmetics, drugs active ingredients, pharmaceutical companies, medical catalogs.
Pharmaceutical Payment Methods
AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0) and a revised Interactive Resource Library provide an unbiased description and analysis of the multiple methods used by public and private sector programs to purchase pharmaceutical products and pay providers who prescribe and dispense them. (Source: SMCP, 2009)
Pharmacoeconomics - the importance for pharmacists
Basic overview of the use of pharmacoeconomics and outcomes research data for pharmacists
Pharmacoeconomics to Get Bigger Budgets, According to Preliminary Survey Results
This year, drug makers' pharmacoeconomics groups will spend more money than ever before -- a clear sign of the function's growing importance to success in the pharmaceutical and biotechnology sectors. (Source: Marketwire, 2/15/2010)
Pharmacy Schools
Pharmacy career resource featuring a school directory, pharmacy articles, and career guide. Research schools and request FREE information
PharmacyChoice.Com
Pharmacist news, jobs, industry information, etc. Great meta-site.
PharmacyNOW
Superb mentoring and employment site for pharmacy professionals. Jobs, salaries, discussion, audio interviews with high-profile pharmacy mentors, and much more.
PharmaModel from Alliance
Patient-based and disease-specific market model,intuitive and easy to update, maintain or refine on an ongoing basis and can be used on a national, regional or international level. It accommodates up to 52 ountries, with country-specific data gathering possibilities, allowing free inputs for data gaps. Impacts of any market update and any epidemiologic, treatment or label changes are immediately accounted for.
PharmDUR
Pharmaceutical auditing company, specializing in Physician Academic Detailing, Patient Drug Utilization Reviews, and Pharmacy Verification Audits.
PharmWeb
Extensive site for "all things pharmacy" (newsgroups, databases, schools, chat, etc.)
Proceedings of Value-Based Health Care Leadership Forum
On February 4, 2009, a meeting was hosted by the Foundation for Managed Care Pharmacy (FMCP), Alexandra, Virginia, and The Pharmacy & Therapeutics Society (P&T Society), Glastonbury, Connecticut, at which health care executives convened to create new knowledge and develop strategies on the role of pharmaceuticals in a value-based health system. This invitation-only event assembled key stakeholders to address critical issues related to value-based health care for 2009 and beyond. The key program objective was to develop strategies on the role of pharmaceuticals in a value-based health care system, with the goal of improving public health. Download report from this URL
Product Approvals: FDA
Monthly listing.
Promotional Spending for Prescription Drugs
Pharmaceutical companies’ efforts to promote prescription drugs have attracted the attention of policymakers because such activities may affect the rate at which different drugs are prescribed and consumed, the total amount spent on health care, and, ultimately, health outcomes. Those promotional activities—usually undertaken on behalf of brand-name, rather than generic, drugs may influence consumers and health care professionals through a variety of channels. (Source: Sheila Campbell, CBP: Economic and Budget Issue Brief, Dec. 2, 2009)
Promotional Spending for Prescription Drugs
Pharmaceutical companies' efforts to promote prescription drugs have attracted the attention of policymakers because such activities may affect the rate at which different drugs are prescribed and consumed, the total amount spent on health care, and, ultimately, health outcomes. (Source: Sheila Campbell, CBO - Economic and Budget Issue Breif, Dec. 2, 2009)
Risk Evaluation and Mitigation Strategies
REMS for drug products may affect marketing and access. Free article download. (Source: Risk Management, Sept 2009)
RPhWorld.Com
Searchable collection related to daily practice. Includes renal dosing, drug interaction checks, drug use in pregnancy, and toxicity antidotes.
Rx List
Free, searchable database of more than 4,000 prescription and over the counter (US) drug products on the web. Currently contains simple information, such as generic and brand name, and therapeutic category. Contains Top 200 prescribed drugs.
Schools of Pharmacy: Directory based on PharmWeb
Worldwide listing in searchable database.
Spending on new drug development
Updates annual drug development expenditures. Average expenditure on drugs in human clinical trials is around $27m per year, with $17m per year on drugs in Phase I, $34m on drugs in Phase II and $27m per year on drugs in Phase III of the human clinical trials. (Source: Christopher Paul Adams and Van Vu Brantner, Health Economics, Feb. 26 2009)
Substitution, Spending Offsets, and Prescription Drug Benefit Design
This award winning article studies how changes in consumers’ co-payments for prescription drugs affect use of and expenditure on prescription drugs, inpatient care, and outpatient care. (Source: Berkley Electronic Press, Forum for Health Economics & Policy: Vol. 10: Iss. 2 Article 4)
Tables for Presribed Drugs by total purchases
Tables for Presribed Drugs by total purchases. (Source: AHRQ -- MEPS, Nov 2009)
Take the lead on late-phase studies, urges Quintiles executive
Pharma Co's must "get a grip" on late-phase research, or other groups (e.g., payers, FDA) will do it for you, and decisions will be based on price! The article cites the recent head-to-head clinical trial of the blood thinners Plavix (clopidogrel, Bristol-Myers Squibb/Sanofi Aventis) and Effient (prasugrel, Eli Lilly/Daiichi Sankyo) conducted by Medco. (Source: PharmaTimes, Dec. 9, 2009)
The AMCP Format for Formulary Submissions, Version 3.0
A Format for Submission of Clinical and Economic Evidence of Pharmaceuticals in Support of Formulary Consideration FMCP Format Executive Committee
The role of pharmacoeconomics in Pharmaceuticals Pricing Board decision-making (PPT Presentation)
Discusses Pharmaceuticals Pricing Board, decision-making in the PPB, and health economic evaluations in decision-making
US Pharmacopoeia
Official public standards-setting authority for all prescription and over-the-counter medicines, dietary supplements, and other healthcare products manufactured and sold in the United States.
USA’s Budget Office reviews promotional spending for prescription drugs
The US Congressional Budget Office (CBO) has released a brief highlighting trends in promotional spending for prescription drugs and market characteristics that influence promotional strategies. (Source: The Pharma Letter
USA’s Budget Office reviews promotional spending for prescription drugs
This article discusses findsing of CBO's investigation of Pharma's spending on marketing to physicians and DTC (direct to consumer)channels. (Source: The Pharma Letter, Dec. 2009)




 

Insurance Resources: Even healthy people need life insurance.
Get life insurance quotes today.

Shop and compare insurance quotes online

 

sponsored by































Become a sponsor



How are we doing? Take our survey





Copyright © 2007, HealthEconomics.Com